Nithin Karakala
Professor
Also affiliated: Emory University (2017); Medical University of South Carolina (2011–2016); University of Arkansas Medical Center (2016–2017); University of Arkansas System (2022–2023); Central Arkansas Veterans Healthcare System (2016–2021); Ralph H. Johnson VA Medical Center (2012); Durham VA Medical Center (2013); John L. McClellan Memorial Veterans Hospital (2021)
Faculty Researcher
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Nithin Karakala's research program focuses on identifying and validating biomarkers for acute kidney injury (AKI) and other renal diseases. He has investigated urinary neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic and prognostic marker for AKI in patients with cirrhosis, and explored the role of SOD1 as a prognostic biomarker for AKI following cardiothoracic surgery. His work also includes studying urinary complement C3 and vitamin D-binding protein for predicting adverse outcomes in AKI patients after cardiac surgery.
Dr. Karakala's clinical interests encompass continuous renal replacement therapy (CRRT), early prognostic markers of AKI, and volume management in AKI. His publications also cover the treatment of hepatorenal syndrome with terlipressin and the use of point-of-care ultrasound in acute care nephrology. He has a h-index of 13 with 44 total publications and 671 citations. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Luis A. Juncos, Joseph H. Holthoff, Manisha Singh, and Abedalrahman Almashayekh.
Research Overview
Dr. Karakala is an Assistant Professor of Medicine in the Division of Nephrology, Department of Internal Medicine. He received his medical degree from Deccan College of Medical Sciences in India. He completed his internal medicine residency at Greater Baltimore Medical Center in Maryland and his nephrology fellowship training at Medical University of South Carolina. He served as the Chief Nephrology Fellow at MUSC as well. Dr. Karakala was on the faculty at MUSC for two years before coming to UAMS. Dr. Karakala is board certified in internal medicine and nephrology. His clinical interests are continuous renal replacement therapy, early prognostic markers of acute kidney injury, and volume management in acute kidney injury. His research interests include biomarkers in renal disease.
Metrics
- h-index: 13
- Publications: 44
- Citations: 680
Selected Publications
-
Response to Letter to the Editor “Gastrointestinal Mucosal Cell Injury Caused by Sevelamer " (2026)
-
Perfusion Under Pressure: Reversing Anuric AKI with Targeted Intra-Abdominal Pressure (IAP) Reduction (2025)
-
Protective Phosphorus Ranges for Major Adverse Cardiovascular Events in CKD: Insights from Spline-Based Survival Models (2025)
-
Calculated Preemptive Strike: Solving Overcorrection of Hyponatremia with Math and Medicine (2025)
-
Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients (2025)
-
SGLT2 Inhibitors as a Therapeutic Option for Both Acute and Chronic Refractory Hypomagnesemia in Diabetic and Nondiabetic Patients: A Multicenter Case Series (2025)
-
The role of IGFBP-1 in the clinical prognosis and pathophysiology of acute kidney injury (2025)
-
Gastrointestinal Mucosal Cell Injury Caused by Sevelamer Crystals: Case Series and Literature Review (2025)
-
Urine Chemistry: A Valuable Link Binding Kidney Physiology to Patient Care (2024)
-
Stepwise Teamwork Approach Saves Patients Extensive Work-Up (2024)
-
Urinary Complement C3 and Vitamin D-Binding Protein Predict Adverse Outcomes in Patients with Acute Kidney Injury after Cardiac Surgery (2024)
-
I Am in a Crystal Bind! A Case that Gave Us Ulcers (2023)
-
The Drug that Keeps Giving: Hypomagnesemia Fixed by SGLT2 Inhibitor (2023)
-
SOD1 is a novel prognostic biomarker of acute kidney injury following cardiothoracic surgery (2023)
-
High-Cutoff Hemodialysis Therapy for Patients with Light Chain Cast Nephropathy and AKI Requiring Dialysis: CON (2023)
Grants & Funding
As listed on this researcher's institutional profile.
- Clinical Scientist Award UAMS Principal Investigator
- Targeting Abdominal Perfusion Pressure in Septic Shock (The MAP APP Study) IRB 228252 Potrero Medical via Biomedical Research Foundation - Arkansas Principal Investigator
Collaboration Network
Top Collaborators
- Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
- Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
- Vascular access, membranes and circuit for CRRT
- Point-of-Care Ultrasound in Acute Care Nephrology
- SOD1 is a novel prognostic biomarker of acute kidney injury following cardiothoracic surgery
Showing 5 of 8 shared publications
- SOD1 is a novel prognostic biomarker of acute kidney injury following cardiothoracic surgery
- Urinary Complement C3 and Vitamin D-Binding Protein Predict Adverse Outcomes in Patients with Acute Kidney Injury after Cardiac Surgery
- The Drug that Keeps Giving: Hypomagnesemia Fixed by SGLT2 Inhibitor
- The role of IGFBP-1 in the clinical prognosis and pathophysiology of acute kidney injury
- Urine Chemistry: A Valuable Link Binding Kidney Physiology to Patient Care
Showing 5 of 7 shared publications
- SOD1 is a novel prognostic biomarker of acute kidney injury following cardiothoracic surgery
- Urinary Complement C3 and Vitamin D-Binding Protein Predict Adverse Outcomes in Patients with Acute Kidney Injury after Cardiac Surgery
- The role of IGFBP-1 in the clinical prognosis and pathophysiology of acute kidney injury
- Protective Phosphorus Ranges for Major Adverse Cardiovascular Events in CKD: Insights from Spline-Based Survival Models
- Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
- Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
- Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
- Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
- Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
- Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
- Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
- Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
- Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
- Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
- Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
- Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
- The Drug that Keeps Giving: Hypomagnesemia Fixed by SGLT2 Inhibitor
- I Am in a Crystal Bind! A Case that Gave Us Ulcers
- Stepwise Teamwork Approach Saves Patients Extensive Work-Up
- Gastrointestinal Mucosal Cell Injury Caused by Sevelamer Crystals: Case Series and Literature Review
- The Drug that Keeps Giving: Hypomagnesemia Fixed by SGLT2 Inhibitor
- I Am in a Crystal Bind! A Case that Gave Us Ulcers
- Calculated Preemptive Strike: Solving Overcorrection of Hyponatremia with Math and Medicine
- Protective Phosphorus Ranges for Major Adverse Cardiovascular Events in CKD: Insights from Spline-Based Survival Models
- Perfusion Under Pressure: Reversing Anuric AKI with Targeted Intra-Abdominal Pressure (IAP) Reduction
- Calculated Preemptive Strike: Solving Overcorrection of Hyponatremia with Math and Medicine
- Protective Phosphorus Ranges for Major Adverse Cardiovascular Events in CKD: Insights from Spline-Based Survival Models
- Perfusion Under Pressure: Reversing Anuric AKI with Targeted Intra-Abdominal Pressure (IAP) Reduction
- Vascular access, membranes and circuit for CRRT
- Point-of-Care Ultrasound in Acute Care Nephrology
- Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
- Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
- Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
- Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
- Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
- Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
Similar Researchers
Based on overlapping research topics